SNIPR receives USD 5.48 million funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials
The 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation